OOIR: Observatory of International Research

Papers

(The median citation count of Seminars in Hematology is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
CAR T-cell therapy comes of age: Introductory editorial for the special issue	63
Special issue on chronic lymphocytic leukemia: Prognostication and therapeutic options introductory editorial	62
Extramedullary myeloma in the era of CAR T-cell and bispecific antibody therapies	54
Clonality in immune aplastic anemia: Mechanisms of immune escape or malignant transformation	49
Clinical applications of circulating tumor DNA in Hodgkin lymphoma	46
Clonal hematopoiesis and VEXAS syndrome: survival of the fittest clones?	45
Insights from the 12th International Workshop on Waldenstrom's Macroglobulinemia	45
Epidemiology and etiology of diffuse large B-cell lymphoma	43
The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19	39
How to set up a clinical research center in Brazil, as an example of a middle-income country	38
Somatic mutations in “benign” blood diseases	31
Lessons learned from the Eµ-TCL1 mouse model of CLL	29
Immune-driven clonal cell selection at the intersection among cancer, infections, autoimmunity and senescence	26
The future of lymphoma diagnosis, prognosis, and treatment monitoring in countries with limited access to pathology services	22
The role of viruses in HIV-associated lymphomas	21
Antibody and immunotherapy in diffuse large B-cell lymphoma	20
Intestinal microbiome and myelodysplastic syndromes: Current state of knowledge and perspectives for future	19
TET2 mutation as prototypic clonal hematopoiesis lesion	19
Accelerating accessibility of CAR-T/NK therapies – Are AlloCARs and rapid manufacturing platforms the road ahead in improving access in multiple myeloma?	18
Vaccinations in patients with chronic lymphocytic leukemia	17
Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors	17
The molecular map of CLL and Richter's syndrome	17
outside front cover, PMS 8883 metallic AND 4/C	15
outside front cover, PMS 8883 metallic AND 4/C	15
Tribute to an editor: Neal S. Young As a Medical Editor and Writer	14

Clonal hematopoiesis	13
At the cusp of a cure in Myeloma: Insights into pathogenesis, modeling and therapeutics	13
Management of Myelodysplastic Syndrome in Pregnant Patients: Treatment Approaches and Considerations	12
outside front cover, PMS 8883 metallic AND 4/C	12
B-cell receptor immunoglobulin stereotypy in chronic lymphocytic leukemia: Key to understanding disease biology and stratifying patients	12
Cellular and immunotherapies for myelodysplastic syndromes	12
Aplastic anemia: Quo vadis?	11
Report of Consensus Panel 3 from the 11th International workshop on Waldenström's Macroglobulinemia: Recommendations for molecular diagnosis in Waldenström's Macroglobulinemia	10
The biology of classical Hodgkin lymphoma	10
Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead	10
Challenges and opportunities of CAR T-cell therapies for CLL	10
Access to essential therapy for sickle cell disease in Africa: Experience from a national program in Ghana	9
Mobilizing CARs: Benefits, drawbacks, and directions for outpatient CAR T-cell therapy	9
The psychiatric and psychological sequelae of vaccine-induced immune thrombotic thrombocytopenia (VITT)	9
A tower of babel of acronyms? The shadowlands of MGUS/MBL/CHIP/TCUS	8
The pediatric approach to Hodgkin lymphoma	8
VEXAS within the spectrum of rheumatologic disease	8
Genetics of somatic auto-inflammatory disorders	8
Menin inhibition for the treatment of acute leukemia	8
Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom’s Macroglobulinemia	7
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trials	7
Understanding MDS stem cells: Advances and limitations	7
DLBCL arising from indolent lymphomas: How are they different?	7
Somatic compensation of inherited bone marrow failure	7
The spectrum of somatic mutations in large granular lymphocyte leukemia, rheumatoid arthritis, and Felty's syndrome	7
Somatic mutations in acquired pure red cell aplasia	7
Clinical applications of circulating tumor DNA in central nervous system lymphoma	6
Measurable residual disease after CAR T-cell therapy	6
outside front cover, PMS 8883 metallic AND 4/C	6
Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with high-risk disease	6
Modernizing multiple myeloma clinical trial eligibility to improve equity and inclusivity by hematological parameters	6
The crossroads of cancer therapies and clonal hematopoiesis	6
miRNA Biology in Chronic Lymphocytic Leukemia	5
License for a CAR T: Examining patient eligibility	5
Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress	5
outside front cover, PMS 8883 metallic AND 4/C	5
outside front cover, PMS 8883 metallic AND 4/C	5
Clonal hematopoiesis in the setting of hematopoietic cell transplantation	5
Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients	5
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients	5
Infectious complications of chimeric antigen receptor (CAR) T-cell therapies	5
Forging international collaboration and alliances to establish the largest transplant center in the north of Vietnam	5
Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa	5
Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria	5
Updates on the biology of chronic lymphocytic leukemia: introductory editorial	4
The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era	4
Platelet-activating anti-PF4 disorders: An overview	4
Role of the tumor microenvironment in CLL pathogenesis	4
The case for prioritizing malignant hematology services in low- and middle-income countries	4
Highlights of the 11th International Workshop on Waldenstrom's Macroglobulinemia: What we learned, and how it will impact scientific discovery and patient care	4

Measurable residual disease monitoring in acute myeloid leukaemia: Techniques, timing and therapeutic implications	4
Melanoma antigen genes (MAGE); novel functional targets in multiple myeloma	4
Toward a pathophysiology inspired treatment of VEXAS syndrome	4
AML diagnostics in the 21st century: Use of AI	4
Collaborations, colleagues, and friendships: The Hematology Branch and blood disease centers in Asia	4
Inflammation in myelodysplastic syndrome pathogenesis	4
RNA splicing as a therapeutic target in myelodysplastic syndromes	4
Special edition of the Seminars in Hematology series on Global Hematology Care	4
Tuning CAR T-cell therapies for efficacy and reduced toxicity	4
The Road More or Less Traveled- Examining the Role of Consolidative Allogeneic Hematopoietic Stem Cell Transplantation After Chimeric Antigen Receptor T Cell Therapy in B-cell ALL	3
Special issue on circulating tumor DNA: Introductory editorial	3
Resolving leukemic stem cell heterogeneity and plasticity with single-cell multi-omics	3
Characteristic bone marrow findings in patients with UBA1 somatic mutations and VEXAS syndrome	3
outside front cover, PMS 8883 metallic AND 4/C	3
Applications of virus-specific T cell therapies post-BMT	3
The Management of older patients with Hodgkin lymphoma: implications of S1826	3
Infections and antimicrobial prophylaxis in patients with myelodysplastic syndromes	3
Inequalities in access to treatment in Argentina: Differences in management of CLL and multiple myeloma?	3
Characterization of Anti-CD3 Antibodies in Clinically Available Bispecific T Cell Engagers	3
masthead	3
Patient-reported outcomes in early phase trials for patients with myelodysplastic syndromes	2
The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors	2
Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT)	2
Cell-free DNA in large B-cell lymphoma: MRD and beyond	2
Beyond SARS-CoV2, the role of viruses in the pathogenesis of hematologic malignancies	2
Clinical manifestations of clonal hematopoiesis: What has SF3B1-mutant MDS taught us?	2
Introduction to series: Diffuse large B-cell lymphoma	2
Gene editing for sickle cell disease and transfusion dependent thalassemias- A cure within reach	2
The genomic landscape of acute myeloid leukemia: Redefining classifications, ontogeny, and therapeutic strategies	2
Smoldering multiple myeloma: Integrating biology and risk into management	2
Secondary and therapy-related acute myeloid leukemias: Overlapping features, distinct trajectories	2
Immunocompetent mouse models of multiple myeloma	2
Clinical picture of VITT	2
Extranodal natural killer/T-cell lymphoma: An overview on pathology and clinical management	2
Palliative care needs of patients with hematologic malignancies and family caregivers and challenges of palliative care provision in Asia: A review of evidence	2
Immunosuppressive therapy in severe aplastic anemia	2
outside front cover, PMS 8883 metallic AND 4/C	2
Beyond HMAs: Novel Targets and Therapeutic Approaches	2
outside front cover, PMS 8883 metallic AND 4/C	2
Biological, prognostic, and therapeutic impact of the epigenome in CLL	2
Mouse models of CLL: In vivo modeling of disease initiation, progression, and transformation	2